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Abstract
Background: BRCA1 gene inactivation causes chromosomal instability, leading to rapid accumulation of
chromosomal rearrangements and mutations. The loss of BRCA1 function due to either germline/somatic mutation
or epigenetic silencing is observed in most high-grade serous carcinomas of the ovary.
Methods: DNA ploidy and gene expression profile were used in order to compare gross genomic alteration and
gene expression pattern between cases with BRCA1 loss through mutation, BRCA1 epigenetic loss, and no BRCA1
loss in cases of high-grade serous carcinoma with known BRCA1 and BRCA 2 status.
Results: Using image cytometry and oligonucleotide microarrays, we analyzed DNA ploidy, S-phase fraction and
gene expression profile of 28 consecutive cases of ovarian high-grade serous adenocarcinomas, which included 8
tumor samples with BRCA1 somatic or germline mutation, 9 samples with promoter hypermethylation of BRCA1,
and 11 samples with no BRCA1 loss. None had BRCA2 mutations. The prevalence of aneuploidy and tetraploidy
was not statistically different in the three groups with different BRCA1 status. The gene expression profiles were
also very similar between the groups, with only two genes showing significant differential expression when
comparison was made between the group with BRCA1 mutation and the group with no demonstrable BRCA1 loss.
There were no genes showing significant differences in expression when the group with BRCA1 loss through
epigenetic silencing was compared to either of the other two groups.
Conclusions: In this series of 28 high-grade serous carcinomas, gross genomic alteration characterized by
aneuploidy did not correlate with BRCA1 status. In addition, the gene expression profiles of the tumors showed
negligible differences between the three defined groups based on BRCA1 status. This suggests that all ovarian
high-grade serous carcinomas arise through oncogenic mechanisms that result in chromosomal instability,
irrespective of BRCA status; the molecular abnormalities underlying this in the BRCA intact tumors remains
unknown.
Background
In the western world, ovarian cancer is the leading cause
of death among patients with gynecological cancers [1].
High-grade serous carcinoma accounts for 70% of all
ovarian cancers, and a disproportionate number of
deaths as these tumors are more likely to present with
advanced stage disease [2]. Germ line mutations of
BRCA1 or BRCA2 genes predispose primarily to high-
grade serous carcinoma of the ovary and approximately
16% of high-grade serous carcinoma is associated with
germ line BRCA gene mutation [3]. BRCA1 gene inacti-
vation is caused either through mutation or epigenetic
silencing by promoter hypermethylation, in contrast to
BRCA 2 gene where promoter hypermethylation does
not significantly contribute to loss of function [4].
Operating as tumor suppressor genes, the primary
function of BRCA genes is to preserve the structural
and numerical stability of chromosomes during cell divi-
sion [5]. The proteins are expressed in the dividing cells
and located in the nucleus. BRCA1, by forming a multi-
protein complex [6], senses double strand DNA breaks
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free homologous recombination [7,8]. BRCA2, on the
other hand, functions as a specific mediator of the inter-
actions leading to homologous recombination [9]. In
absence of functional BRCA1 or BRCA2, double stand
DNA breaks are repaired by error-prone non-homolo-
gous end joining mechanism leading to further muta-
tions and genomic instability [10]. According to the
chromosomal instability model for the pathogenesis of
BRCA-associated cancers, genetic alterations causing
loss of cell-cycle checkpoints and chromosomal instabil-
ity are crucial during oncogenesis [11,12]. Chromosomal
instability can be assessed by degrees of aneuploidy [13]
and DNA ploidy related parameters [14]. Gross genomic
alteration evidenced by aneuploidy is usually the result
of chromosomal instability [15].
Earlier, by analyzing BRCA1 mutation, expression and
promoter hypermethylation, we proposed a potential
subclassification of high-grade serous adenocarcinomas
into three groups: BRCA 1 loss through mutation,
BRCA1 epigenetic loss and no BRCA loss [16]. Thera-
peutically, the subclassification might be useful for
tumors susceptible to targeted treatment with inhibitors
of poly (ADP-ribose) polymerase (PARP1) [17]. In order
to determine associations between BRCA1 loss and
gross genomic alteration, tumor proliferation rate and
gene expression profile, we have evaluated DNA ploidy
and S-phase fraction by high-resolution image cytometry
and gene expression profile using oligonucleotide micro-
arrays, in a cohort of high-grade serous carcinomas with
defined BRCA1 and BRCA2 status.
Methods
Tumors and patients
Samples from the patients with ovarian carcinoma from
January 2004 to September 2005 were collected at the
Vancouver General Hospital in Vancouver, Canada. The
diagnosis of high-grade serous carcinoma was made
morphologically and these cases are a subset of those
previously reported [16]. Ethical approval was obtained
from the University of British Columbia Ethics Board
(#H02-61375 and #H03-70606).
DNA ploidy analysis by image cytometry
Image cytometric DNA ploidy analysis was performed in
the cohort as described previously [18]. Briefly, using 50
micron sections of paraffin embedded tissue, a mono-
layer was prepared and stained with Feulgen method.
The images of the nuclei were captured and integrated
optical density of individual nuclei was measured using
the Fairfield DNA ploidy system. Histograms, made
from the integrated optical density, were classified using
established criteria [18]. The S-phase fraction was
manually calculated by multiplying the number of
channels between mid-G0/G1 and mid-G2/M peaks (C)
by the mean number of registrations per channel in an
even part of the S-phase region (M) and the product
was subsequently was divided by the total number of
nuclei between the beginning of G0/G1 and the end of
G2/M peak (N) expressed in percentage (CxMx100/N)
[19]. In the tumors with aneuploid peaks, the S-phase
fraction of aneuploid subpopulation was estimated. The
S-phase fraction was divided into high and low by using
the median as a cutoff point. The DNA index and coef-
ficient of variation (CV) of the peaks were also
registered.
Oligonucleotide microarrays for gene expression profile
The Human Exonic Evidence Based Oligonucleotide
microarrays (HEEBO, Stanford) were used to study
the global gene expression profiles. Frozen tumors
were available for all except two cases of serous carci-
nomas with no demonstrable BRCA1 loss (case num-
ber 208 and 273). Prior to RNA extraction, frozen
section analysis was performed and all tumor samples
were confirmed to contain viable and representative
tumor with no contaminating normal tissue structures.
Specimens were subsequently homogenized in Trizol
reagent (Invitrogen, Carlsbad, CA, USA) and total
RNA was extracted and reverse transcribed into
cDNA using a mixture of oligo dT (Operon, HPLC
purified) and random hexamer (Amersham, Cat 27-
2166-01) primers with incorporation of amino allyl-
dUTP (Ambion 8439). Cy3 and Cy5 dyes (Amersham
RPN 5661) were used for indirect labeling of the
cDNA from reference RNA (Stratagene, Universal
human reference RNA, Cat 740000) and cDNA from
tumor specimens respectively. After hybridization and
washing, microarrays were scanned on a GenePix 4000
microarray scanner and fluorescence ratios (tumor/
reference) were calculated using GenePix software. To
ensure that the measured signals reflect true readings,
only spots with a ratio of signal over background of at
least 1.5 in the Cy5 or 1.5 in the Cy3 channel were
included. Genes were filtered retaining only those
whose expression levels differed by at least 4-fold
(with respect to the series average in expression level
for individual genes) in at least 3 samples and those
with > 70% available good data. Gene centering was
applied to the expression values across this series of
tumors. The filtered dataset contain a total of 1603
genes (Additional file 1). A less stringent gene filtering
criteria (2-fold difference in 3 samples) was also used
in an attempt to identify genes that display more
subtle variations between the three BRCA1-status
defined groups (6843 genes, Additional file 2). The
complete gene array dataset is available through the
accompanying website (http://smd.stanford.edu/).
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According to the genetic status of BRCA1 gene, we
divided 28 consecutive cases of high- grade serous carci-
noma of the ovary into three groups: BRCA1 loss
through mutation, BRCA1 epigenetic loss and no
BRCA1 loss by analyzing BRCA1 mutation, immuno-
expression and promoter hypermethylation. The techni-
ques used for evaluating the BRCA mutations, loss of
heterozygosity and microsatellite instability at both loci,
mRNA level of BRCA1, immunoexpression of BRCA1
and BRCA1 promoter hypermethylation of the tumors
and results obtained have previously been described
[16]. Briefly, BRCA1 loss through mutation is defined as
germline or somatic mutation with low level of BRCA1
RNA and less than 1% nuclei positive for BRCA1 by
immunohistochemistry. Cases with epigenetic BRCA1
loss show ≥4% fully methylated molecules, low level of
BRCA1 RNA and less than 1% nuclei positive for
BRCA1 in immunohistochemistry, with no BRCA1 or
BRCA2 mutations. The no BRCA1 loss cases showed
more than 1% nuclei positive for BRCA1 in immunohis-
tochemistry and average RNA expression, and lacked
either BRCA1 or BRCA2 mutations (somatic or germ-
line) [16]. None of these tumors have BRCA2 mutations.
Statistical analysis
Statistical analysis was performed using SPSS version 16.
Fishers exact test was used to assess the association
between the variables. Statistical significance was
reached at p < 0.05. For gene expression profile data,
unsupervised hierarchical clustering analysis and signifi-
cance analysis of microarrays (SAM) were performed as
described previously [20,21] and a false-discovery rate
(FDR) of less than 5% was considered significant in the
SAM analysis for the current study.
Results
Gross genomic alteration by DNA ploidy
DNA ploidy analysis was performed in 28 BRCA1 and
BRCA 2 defined cases using an image cytometric
method. The mean coefficient of variation of the diploid
peaks was 3.31 (range 1.17-5.16) and that of aneuploid
peaks was 3.36 (range 2.02-5.86). The mean number of
nuclei analyzed was 901. Aneuploidy and tetraploidy
were detected in 12 (42.9) and 7 (25%) samples respec-
tively. The prevalence of aneuploidy and tetraploidy was
not statistically different in the samples with BRCA 1
loss through mutation, BRCA 1 epigenetic loss and no
BRCA loss (Table 1). The DNA index of all the aneu-
ploid tumors was ≥ 1.4 (Figure 1) and in 2 samples it
was more than 2.1. Three tumors with microsatellite
instability [16] were diploid, including two with epige-
netic loss (number 344 and 345) and one with BRCA1
mutation (number 223).
S-phase
The proliferation fraction of the tumors was evaluated
manually from the histograms. S-phase fraction was
divided into two groups, low and high, using median
cutoff value 8.41. Even though BRCA1 loss through
mutation shows low S-phase compared to others, the
frequency of low and high S-phase in subgroups of
BRCA1 status was not statistically different (Table 2).
Gene expression profile
Global gene expression profiles could be analyzed for 26
of the 28 BRCA1 defined cases (8 with BRCA1 muta-
tion, 9 with BRCA1 epigenetic loss through promoter
hypermethylation and 9 with no demonstrable BRCA1
loss). Hierarchical clustering analysis showed no clear
separation of the three BRCA1-defined groups based on
the expression profiles of the filtered gene set (Figure 2).
The gene expression levels of the three BRCA1-defined
groups were directly compared to each other by SAM
analysis. As shown in Table 3, only a small number of
differentially expressed genes were identified by SAM
comparison between the three BRCA1-defined groups
with a FDR < 5% (list of genes with a FDR < 20%
shown in Additional file 3). Comparisons between the
group with BRCA1 mutation versus the group with
BRCA1 epigenetic loss and between the group with
BRCA1 epigenetic loss versus the group with no BRCA1
loss showed no genes with significant differential expres-
sion between the groups. Two genes (CKMT1B and
KIAA1324) were found to be significantly up-regulated
in the group with BRCA1 mutation compared to the
group with no BRCA1 loss (FDR < 5%). No additional
genes were identified to be differentially expressed (FDR
< 5%) between the three groups using the less strin-
gently filtered dataset though there was a trend for
BRCA1 and a gene that is positively regulated by
BRCA1, AREG [22], to be expressed more highly in the
group with no demonstrable BRCA1 abnormality com-
pared to the other groups (Additional file 4). The same
trend in BRCA1 expression was also observed by qRT-
PCR analysis as reported by us previously [16]. However,
the expression levels of BRCA1 and AREG were not suf-
ficiently homogeneous and distinct in each group for the
difference to be identified as being statistically signifi-
cant. In the case of BRCA1, this may reflect the con-
founding effect of the presence of normal cells in these
samples, which do have BRCA1 mRNA, even though
the tumor cells may lack expression.
Discussion
We found that the gross genomic alteration and gene
expression profiles were similar in high- grade serous
carcinoma of the ovary with BRCA1 loss through muta-
tion, BRCA1 epigenetic loss and no evidence of BRCA1
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critical role in maintaining the genomic stability of cells
[23]. Mouse embryonic fibroblasts carrying targeted
deletion of BRCA1 gene were defective in a G2-M
check point leading to multiple spindle poles within a
single cell resulting unequal segregation of chromo-
somes, abnormal nuclear division and aneuploidy [5].
T h em e c h a n i s mo ft h eg e n e t i ci n s t a b i l i t yi sc a u s e db y
Table 1 BRCA1 status in diploid, aneuploid and tetraploid tumors
BRCA1 status DNA ploidy diagnosis
Diploid(%) Aneuploid(%) Tetraploid(%) Total(%) p value
BRCA1 loss through mutation 2 (25) 3 (37.5) 3 (37.5) 8 (28.6)
BRCA1 epigenetic loss 3 (33.3) 4 (44.4) 2 (22.2) 9 (32.1)
No BRCA1 loss 4 (36.4) 5 (45.5) 2 (18.2) 11(39.3) 0.96
Figure 1 Similar histology and histograms from high-grade serous carcinoma of the ovary with different BRCA1 status. (a1, a2) BRCA1
loss due to genetic mutation. (b1, b2) BRCA1 loss through epigenetic promoter hypermethylation. (c1, c2) no BRCA1 loss.
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the pathways for the repair of double-stranded DNA
breaks during DNA replication. In this process, the
damaged strand is repaired using intact, homologous
sequence as a template [7,8]. BRCA1 acts at the DNA
damaged site as a recruiter of molecules that sense and
repair DNA break and an effector of response to DNA
damage during homologous recombination process [6].
In absence of BRCA1 function, the repair is through an
alternate pathway, nonhomologous end joining, which is
error-prone and mutagenic leading to genetic instability
and aneuploidy [11].
In breast carcinoma, the total number of genomic
changes, as determined by cytogenetics, was found to be
almost two times higher in tumors with BRCA1 muta-
tion than in control group [24]. In ovarian tumors,
increased clonal chromosomal aberrations was observed
in BRCA mutated tumors, compared to BRCA non-
mutant tumors [25]. In that series, all BRCA positive
tumors were serous carcinoma and the BRCA non-
mutant tumors were of different histologic types. It is
well known that the morphologically defined ovarian
carcinomas are distinct diseases with different molecular
events during oncogenesis [12], and it seems likely that
t h i sm a yh a v ec o n f o u n d e dt h ef i n d i n g s .I no r d e rt o
address this, we analyzed a series consisting of only
high-grade serous carcinomas, excluding other subtypes
(including genomically stable low-grade serous carcino-
mas) [19,26]. Furthermore, we have separately evaluated
the tumors with BRCA1 loss due to mutation and due
to epigenetic silencing due to a reported difference in
prognosis [27]. In this series of 28 cases, we have
observed that there is no significant difference in the
distribution of aneuploidy and tetraploidy in the three
subgroups. This indicates that BRCA1 inactivation is
not the only mechanism for the development of aneu-
ploidy in high-grade serous carcinoma of the ovary.
Importantly, none of these cases had BRCA2 mutations
that could account for chromosomal instability. In addi-
tion, all aneuploid tumors had DNA index > 1.4 indicat-
ing genomic unstable tumors [13]. Therefore, the results
indicate a second currently unknown mechanism that
leads to aneuploidy in ovarian serous cancer.
We observed lower S-phase in the group of tumors
with BRCA1 loss through mutation compared to the
other groups. The S-phase of BRCA mutant mouse
embryonic fibroblast cells was significantly lower than
the control cells as determined by flow cytometry[5].
However, ovarian carcinomas with BRCA germ line
mutation had higher proliferation fraction than sporadic
tumors as measured by Ki 67 [28].
BRCA1 and BRCA2 mutated ovarian tumors have dif-
ferent gene expression profiles, however, the gene
expression profile of sporadic ovarian tumor overlaps
with both [29]. In this study, we found essentially no
differences in gene expression profile based on BRCA1
status. Only two differentially expressed genes, out of
thousands examined, were identified in one of the pair-
wise comparisons. This is in keeping with an earlier
finding made by Tone et al on a smaller series of 13
high-grade serous carcinomas (of either ovarian or tubal
origin), where highly overlapping gene expression pro-
files were observed between cases with known BRCA1/2
mutation and/or family history and cases with unknown
familiar status [30]. These genes show no functional
relationship to each other or to the genes known to be
involved in BRCA function and this finding is most
probably due to chance alone. While the relative small
sample sizes (n = 8~9) of the different BRCA1-defined
groups examined here may contributes to the paucity of
Table 2 BRCA1 status in tumors with low and high
S-phase fraction (median cut off 8.4%)
BRCA1 status S-phase
Low (%) High (%) Total (%) p value
BRCA1 loss through mutation 6 (75) 2 (25) 8 (28.6)
BRCA1 epigenetic loss 3 (33.3) 6 (66.7) 9 (32.1)
No BRCA1 loss 5 (45.5) 6 (54.5) 11 (39.3) 0.1
Figure 2 Unsupervised hierarchical clustering of high-grade
serous carcinomas of the ovary with different BRCA1 status.
Based on the expression profiles with 1603 filtered genes, there was
no tendency for tumors to cluster based on BRCA1 status (BRCA1
loss through mutation, BRCA1 epigenetic loss through promoter
hypermethylation, and no demonstrable BRCA1 loss). The length of
the dendrogram arms is inversely proportional to the relatedness of
gene expression between cases.
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largest series examined to date and a larger number of
differentially expressed genes can usually be identified
between different tumor types with similar sample sizes
[31,32]. Therefore, the paucity of differences observed
between these groups of serous carcinomas with differ-
ent BRCA1 status is likely a reflection of intra-group
non-uniformity and inter-group overlap in the gene
expression patterns. In addition, we recently showed
that these groups of ovarian carcinoma classified based
on BRCA1 status also show near-identical miRNA
expression profiles [33]. This absence of distinct pat-
terns of mRNA or miRNA expression in groups with
different BRCA1 status may reflect the rapid divergence
in tumors once they acquire chromosomal instability, so
that every individual tumor is sufficiently unique that
clustering analysis identifies no patterns. As such, their
gene expression profiles irrespective of BRCA1 status all
show significant dysregulation/difference from that of
the putative tissues of origin in normal ovarian surface
epithelium and normal fallopian tube as demonstrated
previously [30,34]. This rapid divergence can also
explain the dearth of differentially expressed genes on
supervised (SAM) analysis, as some consistent abnorm-
alities would have to occur within each group for there
to be differences in gene expression. What this does
indicate, however, is that the same abnormality, chro-
mosomal instability, appears to be present in all groups
of high-grade serous carcinoma analyzed, irrespective of
BRCA1 status. While chromosomal instability can be
accounted for in the BRCA1 mutant and BRCA1 epi-
genetically silenced groups, it will be important to iden-
tify the mechanism in the large group of tumors that
lack BRCA1 or BRCA2 abnormalities and these may
involve BRCA1/2-related mechanism(s) or non-BRCA1/
2 related mechanism(s). PARP inhibitors have been
shown to have activity in tumors with mutations of
BRCA1[35]. PARP inhibitors target base excision repair
mechanisms in the cell [36]. In cells that lack BRCA1 or
BRCA2, homologous repair of double-stranded DNA is
d e f e c t i v ea n dt h es i n g l es t r a n db r e a k st h a tc a n n o tb e
repaired because of PARP inhibition are converted to
double strand breaks in dividing cells; in the absence of
BRCA proteins the double strand breaks are repaired by
non-homologous mechanisms, such as non-homologous
end joining, which is lethal to the cell [17,37]. Thus
PARP inhibition can specifically target cells lacking
BRCA, while sparing normal cells. It remains to be seen
whether PARP inhibitors will be active in high-grade
serous carcinomas with either BRCA1 epigenetic silen-
cing or no evidence of BRCA1 loss, although it is con-
ceivable that such cells may lack homologous repair
functions.
Conclusions
There was no relationship between gross genomic
alteration, detected by high resolution DNA image ana-
lysis, and BRCA1 inactivation in high-grade serous car-
cinoma of the ovary. Gene expression profile analysis
similarly revealed no significant differences between
these groups. This raises two questions. What is the
mechanism underlying genomic instability and develop-
ment of aneuploidy in ovarian high-grade serous carci-
nomas that lack BRCA1 and BRCA2 abnormalities? Will
these tumors, which do have genomic instability, be sen-
sitive to therapy targeted at cells lacking in DNA repair
capability, such as PARP inhibitors?
Additional material
Additional file 1: This is an excel file containing the full data for
1603 genes that met the filtering criteria.
Additional file 2: This is an excel file containing the full data for
6843 genes that met a less stringent gene filtering criteria.
Additional file 3: This is a table showing all the differentially
expressed genes identified by significance analysis of microarray
(SAM) between the different BRCA1-defined groups with a false-
discovery rate (FDR) of < 20%.
Additional file 4: Expression levels of BRCA1 and AREG for all cases.
Expression level is depicted compared to the mean of all samples, with
green indicating lower than mean expression level and red indicating
higher than mean expression level. Black indicates expression at the
mean for the entire group. Gray indicates missing data.
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